Longeveron Appoints Arin Maercks Chief Commercial Officer

Longeveron LLC, a biopharmaceutical company that develops stem cell therapies for aging-related diseases, announced that the company has appointed Arin Maercks as chief commercial officer. Maercks brings to the company a wide breadth of experience in the healthcare sector as a founding executive, operating executive, advisor and investor.

“Arin’s career spans key strategic leadership and advisor roles guiding the growth of emerging companies in healthcare and technology. His extensive experience will be invaluable as we continue our clinical research and progress with development of our stem cell therapies for aging-related conditions, which have become critical as the population grows older,” said Joshua Hare, M.D., Longeveron co-founder and chief science officer.

Prior to joining Longeveron, Maercks served as an operating executive and later as an advisor to CheckedUp, a point of care technology platform to increase patient engagement, where he was responsible for leading corporate development and the commercialization of the company’s beta platform in the ophthalmological sector. Previously, he served as chief operating officer of Lexington International, a medical device company focused on the development and manufacturing of laser instruments to treat dermatological conditions.

Maercks has been instrumental in the successful launches and exits of several consumer-focused companies, including Cosmetic Dermatology Inc./Dr. Brandt Skincare, GoSmile, Inc. and Menscience Androceuticals, a men’s health and wellness company. As a healthcare and technology investor, he has provided strategic counsel on growth and acquisition opportunities to companies including Zesty Health, which was acquired by Square; Loudr, a digital music licensing platform, acquired by Spotify; and LaunchKey, a multifactor authentication platform, acquired by Iovation/TransUnion.

Maercks received an EMBA from Northwestern University – Kellogg School of Management and a BSBA in management and international business from Appalachian State University.

In 2017, Longeveron published positive Phase I and Phase 2 clinical studies in the Journals of Gerontology that evaluated the safety and efficacy of its allogeneic Mesenchymal Stem Cells (MSCs) in patients with Aging Frailty. The company is now recruiting for an expanded Phase 2b Aging Frailty study, a Phase 1 Alzheimer’s trial, and Phase 1 and 2 trials to evaluate the safety and efficacy of its stem cells for improving flu vaccine immune response in Aging Frailty patients.